

# A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis

Paul H. Ratner, MD,<sup>a</sup> Steven R. Findlay, MD,<sup>b</sup> Frank Hampel, Jr., MD,<sup>c</sup>  
Julius van Bavel, MD,<sup>d</sup> Michael D. Widlitz, MD,<sup>e</sup> and  
Jeffrey J. Freitag, MD<sup>e</sup>

San Antonio, Austin, and New Braunfels, Texas, and Princeton, N.J.

**Background:** Azelastine solution is a topically (nasal) administered antiallergy drug with a preclinical profile suggestive of efficacy in patients with allergic rhinitis.

**Objectives:** The study was designed to compare the effectiveness and safety of two dosages of azelastine nasal spray (2 sprays per nostril once daily and twice daily) with that of placebo in the treatment of patients with symptomatic seasonal allergic rhinitis.

**Methods:** Two hundred fifty-one patients (12 years of age or older) were randomized to treatment in this 2-week, double-blind, parallel-group study. Primary efficacy variables were Major Symptom Complex (nose blows, sneezes, runny nose, itchy nose, watery eyes) and Total Symptoms Complex (Major Symptom Complex plus itchy eyes/ears/throat/palate, cough, postnasal drip).

**Results:** Patients treated with azelastine had mean percent improvements in Total and Major Symptom Complex scores that were consistently superior to placebo at each evaluation point. Overall, improvements were statistically significant ( $p \leq 0.05$ ) in the Total Symptoms Complex for both azelastine groups and in the Major Symptom Complex for the twice daily group with a trend toward statistical significance for the once daily group. Azelastine was superior to placebo in improving all individual rhinitis symptoms. Adverse experiences in the azelastine groups were minor and infrequent.

**Conclusion:** The results support the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis. (*J ALLERGY CLIN IMMUNOL* 1994;94:818-25.)

**Key words:** Azelastine nasal spray, symptomatic seasonal allergic rhinitis, Major Symptom Complex, Total Symptom Complex

Azelastine hydrochloride is an investigational antiallergic compound that has been shown in human and animal model systems to inhibit the synthesis or target receptor activity of a broad spectrum of biologic mediators of allergy and airway hyperreactivity including histamine,<sup>1, 2</sup> leukotrienes,<sup>3, 4</sup> TAME-esterase,<sup>5</sup> acetylcholine,<sup>6</sup> se-

#### Abbreviations used:

b.i.d.: Twice a day  
MSC: Major Symptom Complex  
NS: Nasal spray  
q.d.: Once a day  
SAR: Seasonal allergic rhinitis  
TSC: Total Symptom Complex

From <sup>a</sup>Sylvana Research, San Antonio; <sup>b</sup>Findlay Research Associates, Inc., Austin; <sup>c</sup>Private practice, New Braunfels; <sup>d</sup>Allergy Associates of the Austin Diagnostic Clinic; and <sup>e</sup>Wallace Laboratories, Princeton.

Supported by a grant from Wallace Laboratories, a Division of Carter-Wallace, Inc., Cranbury, N.J.

Received for publication July 7, 1993; revised Apr. 19, 1994; accepted for publication May 12, 1994.

Reprint requests: Paul H. Ratner, MD, Sylvana Research, 7711 Louis Pasteur, Suite 406, San Antonio, TX 78229.

Copyright © 1994 by Mosby-Year Book, Inc.

0091-6749/94 \$3.00 + 0 1/1/57589

rotonin,<sup>7, 8</sup> and bradykinin.<sup>9</sup> The effects of inhibiting these mediators include the inhibition of allergic reactions, interference with inflammatory processes, and modulation of airway smooth muscle response. For these reasons, azelastine should be characterized as a multifunctional antiallergic medication because it provides significant therapeutic activity in allergic hayfever and allergic asthma.<sup>10</sup>

Previous short-term studies of azelastine nasal spray (Astelin NS) have shown that dosage regimens of 2 sprays per nostril once a day (q.d.) and 2 sprays per nostril twice a day (b.i.d.) are safe and effective in the treatment of seasonal allergic rhinitis (SAR).<sup>11, 12</sup> These studies also demonstrated that azelastine nasal spray (NS) has a rapid onset of action (within 1 to 2 hours of administration) and a long duration of effect, lasting up to 24 hours.

To alleviate the limiting factors that are often associated with SAR trials (e.g., variability and duration of the pollen counts), this study was conducted in south central Texas where pollen from the tree *Juniperus sabinoide*s, commonly called mountain cedar, is an important cause of respiratory allergy. The mountain cedar pollinates heavily during the months of December, January, and February and somewhat less so in November and March, depending on yearly weather conditions. In the winter months, the pollen from the mountain cedar blows in with "northern fronts" and is the only pollen present in significant amounts in the air during this time. Mountain cedar pollen counts are higher than those observed with any other seasonal pollen. As such, it provides an excellent research model with which to evaluate the efficacy of medications in treatment of pollen-induced respiratory allergy.

In this study, conducted at four sites in south central Texas during the mountain cedar pollen season in January and February, the efficacy and safety of two dosages of azelastine NS were compared with efficacy and safety of placebo in the long-term treatment of patients with symptomatic SAR.

## METHODS

### Patients

All patients were at least 12 years old with a history and diagnosis of allergic rhinitis requiring therapy for at least the previous 2 years and a positive response to mountain cedar pollen, as confirmed by a recognized prick or scratch test within the past year. A signed informed consent document was required before the screening period. The consent document for those under the legal age of consent (18 years) was also signed by a parent or guardian.

Patients with a history of asthma could be enrolled if they had not taken long-term antiasthma medication for at least 24 consecutive months before study entrance or if they had a history of exercise-induced asthma and had used a  $\beta$ -agonist inhaler only in conjunction with exercise. Patients with acute exacerbations of asthma were excluded from study participation.

Pregnant and nursing women were ineligible for participation, and women of childbearing potential were included only if they used appropriate methods of contraception. Patients with an upper respiratory tract infection, with clinically significant nasal anatomic deformities, or with other significant medical conditions were excluded, as were those who experienced an episode of acute sinusitis within 60 days of participation and those receiving a changing immunotherapy regimen or beginning immunotherapy.

The following medications were restricted before the baseline evaluation: calcium channel blockers, cromolyn,  $\beta$ -blockers, reserpine, or monoamine oxidase inhibitors within 14 days;  $H_1$ -receptor antagonists or decongestants within 48 hours; and astemizole within 60 days. Also ineligible for study participation were those patients who had experienced a clinically significant adverse drug reaction during a previous drug study with azelastine or a similar drug.

### Study design

This was a multicenter, double-blind, randomized, placebo- and positive-controlled, parallel-group study in patients with symptomatic SAR. After a 1-week single-blind placebo evaluation period, eligible patients who satisfied the minimum symptom criteria (a Major Symptom Complex [MSC] score of at least 10 on any 4 days of the baseline period with at least one symptom of moderate or greater intensity on each of the 4 days) were randomized to one of four treatment groups: azelastine NS, 2 sprays per nostril q.d. (total daily dose = 0.55 mg), azelastine NS, 2 sprays per nostril b.i.d. (total daily dose = 1.1 mg); chlorpheniramine maleate (Chlor-Trimeton Repetabs) 12 mg b.i.d.; or placebo, b.i.d. for 2 weeks of treatment.

Study medication was blinded with a double-dummy technique for both the NS and tablets. Patients received medication twice a day; at both times, they took the tablet and the NS. For the chlorpheniramine group, the NS was matching placebo, and for the azelastine groups, the tablet was matching placebo.

Rhinitis symptoms were recorded at the time of drug administration (once in the morning and once in the evening) on a diary card. For the symptoms of runny nose and sniffles; itchy nose; watery eyes; itchy eyes, ears, throat, and palate; cough; postnasal drip; and symptom stuffiness the patients used the following scale to rate severity: 0 = none; 1 = mild, symptoms barely noticeable; 2 = modest, symptoms noticeable; 3 = moderate, somewhat bothersome; 4 = moderately severe, interfered with activities; and 5 = severe, constant distraction. For nose blows and sneezes the patients used the following scale to rate the number (and severity) of their symptoms: 0 = none; 1 = 1 to 3 (mild); 2 = 4 to 6 (modest); 3 = 7 to 10 (moderate); 4 = 11 to 15 (moderately severe); 5 = more than 15 (severe).

After 1 and 2 weeks of double-blind treatment, patients returned to the study site for a physical and

**TABLE 1.** Demographic and baseline characteristics

	<b>Azelastine NS q.d. (n = 62)</b>	<b>Azelastine NS b.i.d. (n = 63)</b>	<b>Chlorpheniramine (n = 62)</b>	<b>Placebo (n = 64)</b>
Age (yr)				
Mean	35	39	39	39
Range	12-65	12-70	13-68	13-71
Sex (%)				
Male	47	68	52	52
Female	53	32	48	48
Race (%)				
White	95	97	98	97
Other	5	3	2	3
Weight (lb)				
Mean	158.7	175.5	160.8	163.5
Range	79-237	92-270	95.5-280	90-272.5
Baseline				
Mean TSC	18.2	18.8	18.4	18.6
Mean MSC	12.1	12.5	12.4	12.2

nasal examination and a diary review. A follow-up evaluation was performed 1 week after completion or early discontinuation of double-blind therapy.

The primary efficacy parameters consisted of the Total Symptom Complex (TSC) and MSC severity scores. In general, the TSC consists of the symptoms that are typically part of the rhinitis profile, and the MSC consists of those symptoms most dominant in the rhinitis symptom profile. Five individual symptom scores (runny nose, itchy nose, sneezing, nose blows, and watery eyes) were summed to form the MSC severity score and three additional symptoms (postnasal drip, cough, and itchy eyes/ear/throat/palate) were summed with the MSC to form the TSC severity score.

The changes from baseline for the TSC and MSC severity scores were based on the daily average mean scores. For each evaluation period (at the end of weeks 1 and 2 and at the end of study), the mean for all the morning individual rhinitis symptom scores and the mean for all the evening individual rhinitis symptom scores were calculated for the respective periods. The overall daily average was then calculated on the basis of the mean of the two means. The TSC and MSC severity scores were determined by summing the daily average severity scores for the appropriate individual rhinitis symptoms at baseline and at each evaluation period.

Secondary efficacy parameters consisted of changes in individual symptoms, changes in the TSC severity score that included the additional symptom of stuffiness, the investigators' and patients' global evaluations, the investigators' assessment of rhinitis symptoms, and nasal examination findings. Safety parameters consisted of physical examinations, measurements of vital signs and body weights, clinical laboratory assessments, and adverse experience reports.

The study protocol was approved by a national institutional review board.

### Statistical analysis

Previous azelastine investigations showed that 61 patients per group would be sufficient to detect a difference of 45% between the azelastine mean change and placebo mean change for the TSC severity score with an alpha level of 0.05 and a power of 80%.

The primary analysis was an intent-to-treat analysis, performed with all available patient-response data at each weekly evaluation period. In addition, an end-point analysis, based on each patient's last daily average score during double-blind treatment carried forward, and an overall analysis, based on each patient's average of all available responses during double-blind treatment, were also performed. The mean percent and mean absolute changes from baseline for the TSC and MSC severity scores were analyzed by analysis of covariance, incorporating effects of treatments, center, and their interaction plus the baseline as a covariate. Underlying assumptions such as normality and homoscedasticity of the analysis of covariance model were tested and met.

Treatments were compared by use of two-tailed *t* tests, with the mean square error from the covariance analysis. Treatment differences for global evaluations (investigators' and patients') and changes in nasal examination findings were analyzed by the Cochran-Mantel-Haenszel test.

Within each treatment group, the change from baseline after each week of double-blind treatment was calculated for vital signs, body weights, and laboratory parameters and analyzed by a two-tailed *t* test. Treatment group comparisons were based on an analysis of




FIG. 1. Mean percent improvement in the TSC severity scores during weeks 1 and 2 and at end point.




FIG. 2. Mean percent improvement in the MSC severity scores during weeks 1 and 2 and at end point.

variance, including effects of centers, treatments, and center-by-treatment interaction. The proportions of patients with the most frequently reported individual adverse experiences were compared across the treatment groups by chi square tests. The level of significance for all tests was set at  $p = 0.05$ .

## RESULTS

Two hundred fifty-one patients, ages 12 to 71 years, satisfied the inclusion criteria and were randomized to double-blind treatment. One patient, however, was lost to follow-up, and another patient withdrew before taking any double-blind medication. Thus data from 250 patients were available for the analyses of safety, and data from 249 patients were included in the analyses of efficacy. The patients were randomized in equal numbers to the four treatment groups, and, with the exception of a higher mean baseline body weight in the azelastine NS b.i.d. group, there were no significant differences among the treatment groups for the demographic parameters (Table I).

All 251 patients met the study entry criterion of a minimum MSC severity score. There were no statistically significant differences among the treatment groups at baseline in the mean TSC and MSC values (Table I). The average daily pollen counts for each week during double-blind therapy were very high throughout the study period ( $\geq 1200$  grains/m<sup>3</sup>).

### Primary efficacy parameters

The mean percent improvement in the TSC and MSC severity scores for the active-treatment groups were superior to those for the placebo




FIG. 3. The overall mean percent improvement in the TSC and MSC severity scores and in the TSC score including the additional symptom of stuffiness.

group at each evaluation point (Figs. 1 and 2). After 1 week of treatment, the mean percent improvements in the TSC and the MSC severity scores for the azelastine NS q.d. (20% for both scores) and azelastine NS b.i.d. (27% and 30%, respectively) groups were statistically significantly ( $p \leq 0.05$ ) greater than that observed for the placebo group (7% for both scores).

During week 2, statistical significance versus placebo was maintained for the azelastine NS b.i.d. group for the MSC severity score (36%) and approached statistical significance ( $p \leq 0.10$ ) for the TSC severity score (34%). The mean percent improvements for the azelastine NS q.d. group during week 2 exceeded those for placebo in the TSC and MSC severity scores but were not statistically significant.

**TABLE II.** Contribution of the individual rhinitis symptoms to the MSC and TSC severity scores at baseline and end point

Symptom	Azelastine NS q.d. (n = 62)			Azelastine NS b.i.d. (n = 63)		
	Mean (%) baseline	Mean (%) end point	Percent improvement	Mean (%) baseline	Mean (%) end point	Percent improvement
Runny nose/sniffles	2.80 (15.4)	2.06 (15.8)	26.4	2.84 (15.1)	1.87 (15.0)	34.2
Nose blows	2.65 (14.5)	1.91 (14.6)	27.9	3.05 (16.2)	2.13 (17.1)	30.2
Sneezes	2.45 (13.4)	1.78 (13.6)	27.3	2.55 (13.5)	1.72 (13.8)	32.5
Itchy nose	2.26 (12.4)	1.62 (12.4)	28.3	2.10 (11.2)	1.35 (10.9)	35.7
Watery eyes	1.96 (10.8)	1.38 (10.6)	29.5	1.95 (10.4)	1.03 (8.3)	47.2
MSC	12.12 (66.5)	8.75 (66.9)	27.8	12.49 (66.4)	8.10 (65.2)	35.0
Itchy eyes/cars/throat/palate	2.48 (13.6)	1.62 (12.4)	30.2	2.38 (12.6)	1.48 (11.9)	37.8
Cough	1.18 (6.5)	0.82 (6.3)	30.5	1.57 (8.3)	1.12 (9.0)	28.7
Postnasal drip	2.45 (13.4)	1.88 (14.4)	23.2	2.38 (12.6)	1.73 (13.9)	27.3
TSC	18.23 (100)	13.07 (100)	28.3	18.82 (100)	12.43 (100)	33.9

For the end-point analysis, the mean percent improvements in the TSC and MSC severity scores, respectively, for the azelastine NS q.d. group (28% and 27%) and the azelastine NS b.i.d. group (32% and 34%) exceeded those for placebo (19% and 20%) and were statistically significant (vs placebo) for the azelastine NS b.i.d. group.

Overall, when both treatment weeks were combined (Fig. 3), the mean percent improvements in the TSC (30%), MSC (32%), and TSC with stuffiness (28%) were statistically significant for the azelastine NS b.i.d. group versus placebo (12% to 13%). For the azelastine NS q.d. group, the overall mean percent improvement across both weeks was statistically significant for the TSC severity score (24%) and approached statistical significance for both the MSC severity score (23%) and TSC with stuffiness severity score (22%) versus placebo.

Treatment with 12 mg of chlorpheniramine maleate also resulted in improvements in the TSC and MSC severity scores that were statistically significantly greater than those for placebo after each week of treatment, overall across both weeks, and for the end-point analysis.

### Secondary efficacy parameters

Results of the analyses for the secondary efficacy variables were generally consistent with the pattern of therapeutic responses for the mean percent improvements in the TSC and MSC severity scores. Treatment with azelastine resulted in improvements in all individual symptoms of the TSC severity score. For both azelastine NS groups, the percentage of each symptom's contri-

bution to the total severity score at the end point of the study was similar to its percent contribution at baseline (Table II). Therefore the magnitude of each symptom's improvement for the azelastine NS q.d. and b.i.d. groups was proportional to its contribution to the TSC severity score at baseline.

In addition, across both weeks of treatment, investigators rated a greater majority of patients in the azelastine NS b.i.d. group (84%;  $p \leq 0.05$ ) and the azelastine NS q.d. group (73%) as therapeutically improved when compared with patients in the placebo group (66%). A greater majority of patients in the azelastine NS q.d. and b.i.d. groups (86% and 82%, respectively) also rated their therapeutic response as improved when compared with the placebo group (77%).

### Safety parameters

There were no clinically meaningful within-group changes or between-group differences for any of the treatment groups in vital signs and body weight. Pre- and posttreatment physical examination results were unremarkable. There were no differences between the azelastine NS groups and the placebo group in the percentage of patients who had a change in the nasal examination parameters (nasal secretion and turbinate mucosa). In addition, there were no meaningful between-treatment differences in the pretreatment and end-of-treatment mean laboratory values for adult patients.

Azelastine NS was well tolerated, and only two patients treated with azelastine (both from the azelastine NS b.i.d. treatment group) discontinued therapy because of an adverse experience

**TABLE III.** Number and percent of subjects by treatment who reported treatment-emergent adverse experiences\*

	Azelastine NS q.d. (n = 62)	Azelastine NS b.i.d. (n = 63)	Chlorpheniramine (n = 61)	Placebo (n = 64)
Headache	9 (14.5%)	6 (9.5%)	7 (11.5%)	7 (10.9%)
Dry mouth	2 (3.2%)	3 (4.8%)	2 (3.3%)	0
Somnolence	3 (4.8%)	2 (3.2%)	3 (4.9%)	0
Influenza-like symptom	1 (1.6%)	3 (4.8%)	0	1 (1.6%)
Rhinitis	4 (6.5%)	0	2 (3.3%)	0
Pharyngitis	2 (3.2%)	1 (1.6%)	4 (6.6%)	1 (1.6%)

\*Incidence of adverse experiences was 4% or less in any treatment group.

(dizziness in one, increased blood pressure in the other). The most frequently reported treatment-emergent adverse experiences are shown in Table III. The incidences of the adverse experiences in the azelastine groups were not statistically significant when compared with those for the placebo group.

## DISCUSSION

Allergic rhinitis is a disease that manifests in a complex of many symptoms. Although a single symptom may predominate in any given individual, it is traditional and clinically rational to examine the impact of a drug on the complex of rhinitis symptoms as the best indicator of how patients are responding to the medication (treatment efficacy). Accordingly, the primary efficacy parameters were the MSC severity score, which consisted of the five symptoms that predominate the rhinitis symptom profile, and the TSC severity score, which consisted of the MSC severity score plus three additional rhinitis symptoms. With these symptom complexes, previous studies have shown that azelastine NS (2 sprays per nostril q.d. and b.i.d.) has a rapid onset of action within 1 to 2 hours and a long-lasting duration of effect of 12 to 24 hours.<sup>11, 12</sup>

The results of this long-term trial indicate that azelastine NS is effective long-term therapy for the treatment of patients with symptomatic SAR. Both azelastine groups demonstrated statistically significant improvements in the TSC and MSC severity scores after 1 week of treatment. The b.i.d. regimen was associated with statistically significant improvements in the MSC severity score in week 2 and showed a trend toward statistical significance in the TSC severity score in week 2. Although the q.d. regimen was not statistically significant in the second week of treatment, the improvements were greater than those for the

placebo group. The b.i.d. regimen was associated with statistically significant improvements in the overall and end-point analyses for both the TSC and MSC severity scores. In the overall analysis, the q.d. group had statistically significant improvements in the TSC severity score and showed a trend toward statistical significance in the MSC severity score. This clinical efficacy of azelastine NS in the treatment of symptomatic SAR was demonstrated during a season that had a pollen count higher than those generally observed with other seasonal pollens.

For the TSC severity score including the additional symptom of stuffiness, both azelastine groups also demonstrated improvements from baseline that were greater than those for placebo after both weeks of treatment and in the overall and end-point analyses. The results for the TSC score and the TSC score including stuffiness were similar.

Importantly, the improvements in the TSC and MSC severity scores were the consequence of improvements in all of the individual rhinitis symptoms of the severity scores rather than in only one or a few of the symptoms. As shown in Table II and described above, the magnitude of the effect on each symptom is proportional to its contribution to the total score at baseline. Because allergen exposure affects patients differently, it is beneficial for treatment to have a greater effect on the more intense symptoms than on the less intense symptoms. As shown by the absolute improvement scores, the effect of azelastine is greatest on those symptoms with the greatest contribution to the total score at baseline. It should be further noted that even though azelastine is applied topically (intranasally), it affects the systemic symptoms associated with the allergic disease in addition to the nasal symptoms.

We cannot definitively explain how intranasally

administered azelastine improves eye symptoms. Although passage through the nasolacrimal duct is a possibility, a contributing systemic effect cannot be excluded. Plasma samples for the determination of azelastine levels were not obtained in this study. Other studies have demonstrated that azelastine is present in plasma after intranasal administration, albeit at very low concentrations (data on file, Wallace Laboratories). It is possible that a systemic action of azelastine contributes to the favorable ocular effects seen in this and other studies.

It is also possible that somnolence is the consequence of a systemic effect. Azelastine is not a "classical antihistamine," and although it is not "nonsedating," this side effect is a dose-related phenomenon. The incidence of somnolence with low doses of orally administered azelastine (0.5 mg b.i.d.) approximates that observed with placebo (data on file, Wallace Laboratories). Therefore we expected the incidence of somnolence associated with intranasally administered azelastine to be very low and not dissimilar to that for placebo. Also surprising is the complete absence of somnolence in the placebo group. This observation is unusual for placebo-controlled trials in the population with allergic rhinitis.

The objective of this study was to compare the efficacy and safety of two dosages of azelastine NS with placebo in the long-term treatment of patients with symptomatic SAR. The positive-control group served to validate the study design and to assure that the conditions of allergic rhinitis were truly present and responsive to therapy. Chlorpheniramine maleate (Chlor-Trimeton Repetabs, 12 mg b.i.d.) was selected as the positive control because of its widely recognized efficacy in the symptomatic relief of SAR. The study was not designed nor was sample size sufficient to allow a comparison of the azelastine groups with the positive control group. The purpose of the positive control group was accomplished; chlorpheniramine maleate demonstrated statistically significant improvement in the TSC and MSC severity scores compared with placebo (Figs. 1, 2, and 3). The good response in the positive control group is likely a consequence of the dose of Chlor-Trimeton Repetabs (12 mg b.i.d., the highest dose consistent with its labeling) that was chosen for this study.

Azelastine NS has advantages over presently available topically administered antiallergic medications such as decongestants and corticosteroids. As a topically administered antiallergic medication, azelastine NS demonstrated clinical activity

without nasal mucosal sensitization common to other topical antihistamines and, unlike topical decongestants, produced no rebound effect after discontinuation.<sup>13</sup> Adverse experiences such as epistaxis and nasal burning were few and were mild to moderate in severity. In addition, long-term administration of topical corticosteroids may result in the development of localized infections of the nose and pharynx,<sup>14</sup> and use of excessive doses may suppress hypothalamic-pituitary-adrenal function.<sup>15</sup> This is not a concern with azelastine therapy. Use of azelastine over prolonged periods of time should not be limited by side effects caused by systemic absorption or by the direct nasal application.

This study demonstrated that 2 sprays of azelastine administered q.d. and b.i.d. are effective dosage regimens; however, some patients receiving 2 sprays of azelastine q.d. may require an increase in dosage to 2 sprays b.i.d. with prolonged antigen exposure. Azelastine's favorable safety profile combined with a very rapid onset and prolonged duration of action in the relief of rhinitis symptoms may provide advantages over currently used therapies for the treatment of allergic rhinitis.

We thank Mr. Anup Dam for providing the statistical analyses and Mr. Michael Brockley for his assistance in preparation of this manuscript.

## REFERENCES

1. Chand N, Diamantis W, Sofia RD. Antagonism of leukotrienes, calcium, and histamine by azelastine [Abstract]. *Pharmacologist* 1984;26:152.
2. Chand N, Diamantis W, Sofia RD. Antagonism of histamine and leukotrienes by azelastine in isolated guinea pig ileum. *Agents and Actions* 1986;19:164-8.
3. Chand N, Pillar J, Nolan K, Diamantis W, Sofia RD. Inhibition of 5-HETE, LTB<sub>4</sub>, and LTC<sub>4</sub> synthesis by azelastine and its d- and l-isomers in rat mixed peritoneal cells [Abstract]. *Am Rev Respir Dis* 1987;135:A318.
4. Chand N, Diamantis W, Nolan K, Pillar J, Sofia RD. Inhibition of allergic leukotriene C<sub>4</sub> (LTC<sub>4</sub>) formation by azelastine in actively sensitized guinea pig lung [Abstract]. *Pharmacologist* 1987;29:173.
5. Shin MH, Baroody F, Proud D, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM. The effect of azelastine on the early allergic response. *Clin Exp Allergy* 1992;22:289-95.
6. Achterath-Tuckermann U, Szelenyi I. Azelastine inhibits bronchial hyperreactivity to acetylcholine in guinea pigs. *Experientia* 1988;44:993-6.
7. Chand N, Harrison JE, Rooney SM, Sofia RD, Diamantis W. Inhibition of passive cutaneous anaphylaxis (PCA) by azelastine: dissociation of its antiallergic activities from antihistaminic and antiserotonin properties. *Int J Immunopharmacol* 1985;7:833-8.
8. Chand N, Diamantis W, Mahoney T, Sofia RD. Allergic

- responses and subsequent development of airway hyper-reactivity to cold provocation in the rat trachea: pharmacological modulation. *Eur J Pharmacol* 1988;150:95-101.
9. Yamanaka T, Shoji T, Murakami M, Igarashi T. Effects of azelastine hydrochloride, a new antiallergic drug, on the gastrointestinal tract. *Arzneimittelforschung Drug Res* 1981;31:1203-6.
  10. Perhach JL, Chand N, Diamantis W, Sofia RD, Rosenberg A. Azelastine: a novel oral anti-asthma compound with several modes of action. In: Kay AB, ed. *Allergy and asthma: new trends and approaches to therapy*. Oxford: Blackwell Scientific Publications, 1989:230-48.
  11. Meltzer EO, Weiler JM, Freitag JJ. Evaluation of the safety/efficacy of azelastine nasal spray in seasonal allergic rhinitis [Abstract]. *Clin Exp Allergy* 1990;20(suppl 1):100.
  12. Weiler JM, Meltzer EO, Dockhorn R, Widlitz MD, D'Eletto TA, Freitag JJ. A safety and efficacy evaluation of azelastine and nasal spray in seasonal allergic rhinitis [Abstract]. *J ALLERGY CLIN IMMUNOL* 1991;87:219.
  13. Naclerio RM. Allergic rhinitis. *N Engl J Med* 1991;325:860-9.
  14. Mygind N, Clark TJH, eds. *Topical steroid treatment for asthma and rhinitis*. London: Bailliere Tindall, 1980.
  15. *Physician's Desk Reference*. 48th ed. Montvale, New Jersey: Medical Economics Data, 1994:475-7.

AVAILABLE NOW! The FIVE-YEAR (1986-1990) CUMULATIVE INDEX TO THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY can be purchased from the Publisher for \$48.00. This comprehensive, 188-page reference guide is a current presentation of all topics included in the JOURNAL from January 1986 to December 1990 (volumes 77-86)—the past 10 volumes. It incorporates complete references to over 1500 original articles, abstracts, case reports, letters, editorials, and CME articles. It features 1662 subject headings, under which there are 5863 entries. Each subject entry lists the complete article title, author(s), volume, page, and year of publication. It also includes 5801 author entries, listing contributors, along with their respective titles, author-to-author referral, volume, page, and publication date.

To purchase, call or write: Mosby, 11830 Westline Industrial Dr., St. Louis, MO 63146-3318, or telephone FREE, Subscription Services, 1 (800) 453-4351 or 314-453-4351. PRE-PAYMENT REQUIRED. Make checks payable to Mosby. (All payments must be in US funds drawn on a US bank.) Price: \$48.00 in the US, \$54.35 in Canada, and \$51.00 international (price includes mailing charges).